Bristol Myers Squibb Expands Alzheimer’s Study After Irregularities
Bristol Myers Squibb & Co (NYSE: BMY) recently announced it will be increasing patient enrollment in the ADEPT-2 Phase 3 study. This decision comes in light of unexpected irregularities identified in the study's execution across certain clinical trial sites.
Understanding the ADEPT-2 Study
The ADEPT-2 study is designed as a multicenter, randomized, double-blind, placebo-controlled trial. It focuses on evaluating the safety and efficacy of Cobenfy, which is currently approved for treating schizophrenia in adults, for patients experiencing psychosis associated with Alzheimer's disease dementia.
Purpose and Goals of the ADEPT-2 Trial
This pivotal study aims to assess primary outcomes centered on changes in the Neuropsychiatric Inventory-Clinician (NPI-C) scores, specifically focusing on Hallucinations and Delusions (H+D). It also monitors key secondary outcomes like Clinical Global Impression-Severity (CGI-S), all while tracking the drug's safety and tolerability in comparison to a placebo.
Clinical Findings Prompt Changes
After an exhaustive review of initial trial data, Bristol Myers identified irregularities related to clinical trial execution, which necessitated the exclusion of certain patient data from the main analysis prior to locking the database. An independent review by an external party conducted an interim analysis recommended by the Data Monitoring Committee (DMC) in conjunction with the U.S. Food and Drug Administration (FDA).
Trust in Regulatory Backing
With the DMC's encouragement, the study is set to continue enrollment efforts, expanding the original targeted population. This endorsement from the DMC provides a supportive backdrop for the ongoing commitment to advance the ADEPT program further, maintaining a blind status regarding the study data for Bristol Myers.
Analysts Weigh In
Analyst William Blair highlighted the immense market opportunity linked to the ADEPT-2 study, which investors had eagerly anticipated. The ongoing situation with clinical trials, coupled with recent setbacks in other late-stage programs within Bristol Myers, adds to the tension among stakeholders.
Market Reactions and Future Potential
Analyst Matt Phipps noted that while delays related to clinical site issues typically raise red flags for investors, the backing from the IDMC and the FDA's approval for additional enrollment suggests there could still be encouraging results forthcoming from the data.
Implications for Bristol Myers
Given the mounting pressures faced by BMY shares, Phipps points to the potential positive news stemming from any situation that doesn’t reflect outright failure. This perspective could bolster investor confidence amidst processing the complexities of ongoing clinical trials.
Looking Ahead to Future Results
Anticipation builds as additional results from the ADEPT program concerning Alzheimer’s-related psychosis are slated to be disclosed by the end of 2026. This timeline extends beyond earlier expectations, which had suggested results would be announced by the end of 2025.
Broader Context of Recent Developments
In another significant decision in November, Bristol Myers Squibb and Johnson & Johnson (NYSE: JNJ) decided to halt the Phase 3 Librexia ACS study concerning milvexian, following a preplanned interim analysis. This determination was made on the grounds that the trial was unlikely to meet its primary efficacy endpoint.
BMY Stock Performance: As of their latest disclosures, Bristol-Myers Squibb shares experienced a notable rise of 5.77%, trading at around $51.03, indicating the market’s response to these developments and ongoing strategies.
Frequently Asked Questions
What is the ADEPT-2 study about?
The ADEPT-2 study evaluates the safety and efficacy of Cobenfy in patients with psychosis associated with Alzheimer's disease dementia.
Why did Bristol Myers decide to enroll more patients?
Irregularities in data from certain clinical sites were identified, leading to recommendations to continue enrollment to stabilize the study population.
What are the key endpoints of the ADEPT-2 study?
The primary endpoint addresses Hallucinations and Delusions (H+D), while secondary outcomes include Clinical Global Impression-Severity (CGI-S).
What impact do analysts predict for Bristol Myers shares?
Analysts see potential positive outcomes for BMY shares, with any non-failure being a sign of resilience amid current pressures.
When are additional trial results expected?
Further results from the ADEPT studies are anticipated to be disclosed by the end of 2026.
